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ABSTRACT
Glioblastoma multiforme (GBM) is one of the deadliest cancers of the
brain. Its ability to infiltrate healthy brain tissues renders it difficult to remove
surgically. Furthermore, it exhibits high rates of radio- and chemoresistance,
making the survival rates of patients with GBM poor. Therefore, novel effective
therapies for GBM remain urgently in demand. Niclosamide is an anti-helminthic
drug and recently it has been receiving attention due to its reported anticancer
effects in cancer models, including GBM. Furthermore, camptothecin (CPT) is a
naturally-occurring alkaloid and has been previously reported to be a potential
chemotherapeutic agent by targeting the nuclear topoisomerase I. In the present
study, the possible combined chemotherapeutic effects of niclosamide and CPT
on the human glioblastoma cell line U87 MG was investigated by MTT assay and
western blot analysis. Niclosamide exhibited synergistic activities with CPT to
suppress the proliferation of U87 MG cells. Additionally, niclosamide suppressed cell
proliferation and induced cell death mainly by triggering ER stress and autophagy,
whilst CPT induced cell apoptosis mainly through p53-mediated mitochondrial
dysfunction and activation of the MAPK (ERK/JNK) pathways. Overall, these
findings suggest that co-administration of niclosamide and CPT may provide a
novel therapeutic treatment strategy for GBM.

INTRODUCTION

is that GBM tumors have high incidence of recurrence,
which frequently lead to mortality with a median survival
of only 1–3 years from diagnosis [4, 5]. Therefore,
development of novel and effective therapies are urgently
in demand. One strategy to improve the efficacy of anticancer treatments and/or circumvent chemoresistance
is to simultaneously disrupt multiple known oncogenic
signaling pathways using multiple-target therapeutics.
Over the past number of years, various combinations
of chemotherapeutic agents have been identified to be
viable therapeutic options that outperform monotherapy
[6–8]. Therefore, adequate selection of active drugs
and understanding their corresponding mechanism in
combination will facilitate the development of additional

Glioblastoma multiforme (GBM) is the most
common and aggressive form of brain malignancy in
the central nervous system (CNS) [1–3], of which an
effective pharmacological therapeutic treatment strategy
remains unavailable [1–3]. GBM exhibits high rates of
chemo- and radioresistance and potent capabilities to
infiltrate healthy brain tissues, rendering it difficult to
be removed surgically. Currently available treatment
methods for GBM involves combining surgery with
chemotherapy. However, the overall survival rate for
this disease has not improved to a satisfactory level over
the past three decades. One of the main reasons of this
www.oncotarget.com
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effective chemotherapeutic strategies that can be used for
GBM treatment.
Niclosamide is a Food and Drugs Administrationapproved oral anti-helminthic drug that has been
applied for ~50 years for treating tapeworm infections.
Studies over the past decade have demonstrated that
niclosamide is also a promising chemotherapeutic agent
[9, 10]. In addition, a number of studies have reported that
niclosamide can exert potent anti-proliferative activities
whilst inducing cytotoxicity in a broad spectrum of cancer
cells, including head and neck cancer [11, 12], nonsmall cell lung cancer [11], thyroid cancer [13], prostate
cancer [11], colon cancer [14], ovarian cancer [15], acute
myelogenous leukemia [16], breast cancer [17] and
osteosarcoma [18]. It has been previously demonstrated
that niclosamide can effectively suppress the proliferation/
growth of different types of cancers both in vitro and in
vivo. This was mediated by triggering apoptosis, oxidative
stress and inhibiting the activities of key signaling
pathways, including PI3K/AKT [19], Wnt/β-catenin [20,
21], mTOR [22], NF-κB [16] and STAT3 [11, 19, 23–25].
Furthermore, previous studies have identified a multitude
of anticancer agents that when combined with niclosamide,
can inhibit tumor growth. In particular, the combination of
niclosamide with bicalutamide was found to inhibit the
growth of enzalutamide-resistant prostate cancer tumors,
suggesting that it can be used to treat advanced prostate
cancer [26]. Additionally, niclosamide was observed to
synergize with sorafenib to suppress renal cell carcinoma
cell proliferation and survival [27]. The combination of
niclosamide with enzalutamide was also documented
to significantly induce cell apoptosis whilst inhibiting
cell proliferation, colony formation, cell migration and
invasion. In addition, niclosamide was demonstrated to
reverse enzalutamide resistance in prostate cancer cells
[28]. Oh et al. [29] recently reported that combined
treatment with both niclosamide and temozolomide can
significantly reduce cell viability, stemness and suppress
the invasive capabilities of GBM tumorspheres [29]. In
our previous study, it was also shown that niclosamide
can promote cytotoxicity in human glioblastoma cells by
downregulating the pro-survival PI3K/AKT, STAT3 and
Wnt/β-catenin signal pathways. In addition, niclosamide
treatment was found to increase protein ubiquitination,
endoplasmic reticulum (ER) stress and autophagy in
human glioblastoma cells [19].
Although the anti-cancer activity of niclosamide
and its combination with several anti-cancer agents have
already been reported in various cell models, studies
exploring its potential properties whilst in combination
with chemotherapeutic agents in glioma remain
limited. Therefore, in the present study, the possible
anticancer activity of niclosamide in combination with a
previously identified chemotherapeutic anticancer agent
camptothecin (CPT) in U87 MG cells was examined.
CPT is a naturally-occurring alkaloid derived from the
www.oncotarget.com

plant Camptotheca acuminata that has been reported to
exert a novel mechanism of action of targeting the nuclear
enzyme topoisomerase I [30]. Previous studies have
revealed that CPT and its derivatives, including topotecan
(Hycamptin) and irinotecan (Camptosar), display broad
antitumor activities against various types of tumor cells
both in vitro and in vivo. Specifically, they have been
demonstrated to exhibit anticancer activities against lung
cancer [31], gastric cancer [32], hepatocarcinoma [33],
esophageal cancer [34], colorectal cancer [35] and breast
cancer [36]. In addition to inducing apoptosis in various
cancer cell types [37–39], CPT and its derivatives have
also been reported to induce senescence in colon [38] and
lung cancer cells [40].
Although CPT and its derivatives have been
shown to demonstrate potent antitumor activities,
chemoresistance to the CPT family of drugs frequently
occurs [31, 41, 42]. Furthermore, CPT treatment can
result in severe adverse effects in patients, which worsens
the therapeutic outcome and makes bone marrow
transplantation a common medical practice following
CPT treatment [31, 41, 42]. Strategies proposed to resolve
these issues of overcoming chemoresistance, minimizing
severe adverse effects whilst enhancing efficacy are to
design appropriate combinatorial therapeutic methods
involving CPTs alongside other anticancer agents capable
of targeting a multitude of cellular pathways [42].
Therefore, understanding the underlying mechanism of
combination drug action will facilitate the development of
novel effective chemotherapeutic methods.
In the present study, the effects of niclosamide
and CPT treatment combined on the physiology of the
human glioblastoma cell line U87 MG was investigated.
Niclosamide, CPT and niclosamide and CPT combination
treatment were applied to U87 MG cells. The cell viability
and the effects of niclosamide and CPT on the human
glioblastoma cells were revealed by MTT assay and
western blot analysis. Our findings suggest that combined
niclosamide and CPT treatment can be considered as a
promising strategy for the treatment of GBM in the future.

RESULTS
Effects of niclosamide, CPT and their
combination on cell viability and morphological
changes in U87 MG cells
The individual effects of niclosamide or CPT on U87
MG cell viability were first examined. U87 MG cells were
treated with different concentrations of niclosamide and/
or CPT (0–20 µM) for 48 h. The number of live cells was
then measured using MTT assay. As shown in Figure 1,
marked inhibitory effects on the survival and viability of
U87 MG cells were observed in a dose-dependent manner
compared with those in the control group. Based on
the results of this initial MTT assay, the doses of 5 µM
643
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Effect of niclosamide and CPT on protein
ubiquitination

were selected for both niclosamide and CPT for use in
subsequent combinatorial experimentation. The effects of
niclosamide and CPT combined on cell morphology and
viability were then assessed by comparing with those after
treatment with either agent individually.
As shown in Figure 2A, cell morphology was more
altered by both treatments in combination compared with
that after treatment with either agent alone. Control cells
showed high confluency in the cell monolayer, whereas
treatment with either 5 µM niclosamide or 5 µM CPT
alone induced notable morphological changes. After
treatment with niclosamide, a large proportion of cells
exhibited spherical shapes, reduced cell volumes and cell
densities. By contrast, different morphological changes
were observed after the cells were treated with CPT. CPT
exposure induced senescence-like phenotypes, including
flattened cell shape with enlarged cell bodies and intensive
blebbing. The combined treatment with niclosamide and
CPT induced clear morphological changes, where the
cells tended to be rounder in shape and smaller in size. In
addition, an increased number of cells were observed to be
detached from the surface, resulting in lower cell densities.
Taken together, these observed changes suggest that the
co-treatment of niclosamide and CPT exerted marked
negative effects on U87 MG cell morphology. In terms of
the cell viability assay, U87 MG cells were treated with
5 µM niclosamide and/or 5 µM CPT for 48 h. Treatment
with either niclosamide or CPT alone was found to reduce
cell viability (Figure 2B). By contrast, co-treatment with
niclosamide and CPT significantly reduced cell viability
compared with that after treatment with either agent alone
(Figure 2B), implicating suppressive effects of niclosamide
and CPT co-treatment on the viability of U87 MG cells.
Following this observation of the effects of niclosamide
and CPT co-treatment, analysis was subsequently
performed to investigate the mechanism underlying the
effects of niclosamide and CPT on cell survival.

The ubiquitin-proteasome system has emerged as
an attractive novel cancer chemotherapeutic target. Preclinical studies have previously shown that inhibition
of the proteasome pathway using small-molecule
proteasome inhibitors resulted in cell cycle arrest and
apoptosis in cancer cell lines and murine models of
cancer [43]. In addition, our previous study demonstrated
that niclosamide functioned as a proteasome inhibitor
to potently increase protein ubiquitination and induce
apoptosis in U87 MG cells [19]. Therefore, in the present
study, the effects of CPT on protein ubiquitination in U87
MG cells were evaluated. The quantity of ubiquitinated
proteins were measured by western blotting using
an antibody against ubiquitin. Our results confirm
our previous finding that niclosamide promoted the
accumulation of ubiquitinated proteins (Figure 3A). CPT
also promoted protein ubiquitination in U87 MG cells,
albeit to a lesser extent compared with niclosamide,
although the CPT-induced ubiquitinated protein levels are
significantly higher compared with those in the control
group (Figure 3B). However, the combined treatment
of niclosamide and CPT did not increase the levels of
protein ubiquitination compared with that mediated by
CPT treatment alone.

Niclosamide and CPT induces cell apoptosis in a
p53-dependent manner
Activation of caspase is a typical feature of
apoptotic cell death. Caspase-3 is considered to be
a key executioner caspase that serves a central role
in mediating apoptotic responses [44]. The majority
of chemotherapeutic agents induce tumor cell death
through the caspase activation process. Activation of

Figure 1: Niclosamide (Nicl) and CPT treatments reduce U87 MG cell viability. U-87 MG cells were treated with the indicated
concentrations of niclosamide and CPT for 48 hours. Cell viability was determined by MTT assay. Mean ± S.E.M from five replicates.
***
p < 0.001 vs. control.
www.oncotarget.com
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caspase-3 leads to the cleavage of poly-(ADP ribose)
polymerase (PARP), which is considered to be another
hallmark of apoptosis. Our previous study demonstrated
that niclosamide is able to activate caspase-3 and
subsequent PARP cleavage in a dose-dependent manner
[19]. To determine the combined effects of niclosamide
and CPT on apoptosis and cell death in U87 MG cells,
caspase-3 activation and PARP cleavage was measured
through western blot analysis. After incubation with
niclosamide and/or CPT for 24 h, cell lysates were
examined for protein expression. As shown in Figure
3A, treatment with either niclosamide or CPT alone
led to the increased activation of caspase-3 and PARP
cleavage. However, compared with niclosamide, CPT
was the more potent activator of both caspase-3 and
PARP cleavage. This suggests that CPT mainly causes
cell death in a caspase-dependent manner in U87
MG cells. Further quantitative analysis revealed that
combined treatment with CPT and niclosamide caused

significant increases in the cleavage of caspase-3 and
PARP compared with those after either drug treatment
alone (Figure 3C).
p53 is a well-known tumor suppressor protein
and that is found to be mutated in ~50% of all human
cancers [45]. In addition, p53 mutations have been found
in 87% of all GBM cases [45]. It has also been reported
that various types of cells treated with CPT can undergo
p53-dependent apoptosis [46]. p53 activation has been
previously shown to promote the activation of caspases-3
and -7, causing apoptosis in human glioblastoma cells
[47]. By contrast, p21 is a cell cycle inhibitor that serves
an important role in cell cycle arrest and early senescence.
In a number of cell types, although p53 activation
leads to the induction of p21, p21 can also be regulated
independently of p53 activity [48]. To measure the
expression of p53 and p21 proteins following combined
treatment with niclosamide and CPT, U87 MG cells were
treated with either niclosamide and/or CPT for 24 h.

Figure 2: Niclosamide and CPT treatments induce a change in U-87 MG cell morphology and a significant reduction in
cell viability. (A) Representative images of morphology of U87 MG cells were treated with 5 μM niclosamide (Nicl), 5 μM CPT, and their

combination for 24 and 48 hours. Cells were imaged by phase-contrast microscopy. (B) U87 MG cells were treated with 5 µM niclosamide
(Nicl), 5 µM CPT, and their combination for 48 hours. Cell viability was determined by MTT assay. Data represent the mean ± S.E.M of at
least three independent experiments. ***p < 0.001.
www.oncotarget.com
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Western blot analysis was then performed to detect p53
and p21 protein expression. As shown in Figure 4A and
4B, basal expression levels of p53 and p21 were relatively
low in U87 MG cells. The expression level of p53 in
niclosamide-treated cells showed a weak but significant
increase compared with that in the control. However, the
expression level of p53 in CPT-treated cells was potently
and significantly increased compared with that in the
niclosamide-treated cells. p53 expression after the cotreatment of niclosamide and CPT remained comparable
to that after CPT treatment alone. These data are consistent
with those reported in a previous study reporting that CPT
is a strong p53 protein inducer in a variety of cell lines
[38]. Since p21 is one of the downstream targets of p53,
p21 expression was also examined in niclosamide- and/
or CPT-treated U87 MG cells. As shown in Figure 4A
and 4C, U87 MG cells exposed to CPT for 24 h exhibited
substantially higher levels of p21 compared with that in
control, which was positively associated with those of
p53 expression. However, niclosamide exposure not only
reduced the basal levels of p21 expression compared with
that in control, but also completely abolished the CPTinduced p21 activation as shown in cells co-treated with
niclosamide and CPT.

Apoptosis induced by the mitochondrial apoptotic
pathway typically involves the activation of caspases.
Since both niclosamide and CPT can induce activation of
caspase-3 and PARP cleavage, cytochrome c expression
was next evaluated after exposure to niclosamide and
CPT. As shown in Figure 4A and 4D, cytochrome c
expression was significantly increased in U87 MG cells
following treatment with either niclosamide or CPT,
respectively. In addition, co-treatment with niclosamide
and CPT synergistically increased cytochrome c
expression compared with either treatment alone. Overall,
the levels of cytochrome c expression in niclosamideand CPT-treated cells associated positively with the
expression levels of p53, suggesting that niclosamide
and CPT can induce U87 MG cell apoptosis in a p53dependent manner.

Activation of MAPK (ERK/JNK) signaling
enhances U87 cell toxicity
MAPKs serve important roles in a diverse range of
cellular processes, especially apoptosis and cell survival.
There are three major families of MAPKs: ERK, JNK
and p38 MAPK (p38). Upregulation of JNK signaling has

Figure 3: Niclosamide and CPT induce protein ubiquitination respectively and synergistically enhance caspase-3 and
PARP cleavage. The cell lysates were prepared from U87 cells treated with either 5 μM niclosamide (Nicl), or 5 μM CPT alone, or with
combined treatment for 24 hours and resolved by SDS-PAGE and then immunoblotted with antibodies specific for ubiquitin, cleaved PARP,
and cleaved caspase-3 (A). β-Actin was used as the loading control. The protein levels from Western blot were quantified by densitometry.
(B) Ubiquitinated proteins. (C) Cleaved PARP and cleaved caspase-3. Data represent the mean ± S.E.M. *p < 0.05; ***p < 0.001.
www.oncotarget.com
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been extensively reported to be associated with increased
cytotoxicity in various cell lines, including glioblastoma
[49, 50]. In addition, CPT has been reported to activate
the MAPK pathway to trigger apoptosis in human gastric
cancer cell lines [51]. CPT has also been found to activate
JNK and induce oxidative stress in human non-small cell
lung cancer cells [31]. Our previous study has shown that
niclosamide was able to inhibit the activation of ERK in
U87 MG cells [19]. In the present study, the regulation
of ERK and JNK signaling was focused in the U87 MG
cells. First, the effects of niclosamide and/or CPT on
ERK signaling regulation were assessed. As shown in
Figure 5A, ERK expression and phosphorylation were
downregulated in cells treated with niclosamide alone,
which was consistent with findings from our previous
study [19]. By contrast, ERK phosphorylation was
drastically increased in cells treated with CPT for 24 h.
After niclosamide and CPT co-treatment, the CPT-induced
ERK phosphorylation remained unchanged (Figure 5A).
Next, the potential effects of niclosamide and
CPT on JNK signaling were investigated. Regulation
of JNK appeared to be different from ERK, since both
niclosamide and CPT induced JNK phosphorylation
(Figure 5B). Niclosamide weakly but significantly
increased JNK phosphorylation compared with that in

the control group (Figure 5B). JNK phosphorylation was
also effectively stimulated after CPT treatment for 24 h.
Furthermore, co-treatment with both CPT and niclosamide
significantly enhanced JNK phosphorylation in U87 MG
cells compared with that after either individual treatment
alone (Figure 5B). Therefore, the phosphorylation profile
of JNK was consistent with the aforementioned western
blotting data regarding apoptotic events, namely caspase-3
activation, PARP cleavage and cytochrome c expression
(Figures 3 and 4).
Unlike JNK, activation of ERK can mediate both
protective and harmful effects [52–54]. Therefore, the
role of CPT on ERK signaling was next investigated in
U87 MG cells. To determine the effects of p-ERK1/2 on
apoptosis induction by CPT in U87 MG cells, the ERK
inhibitor PD98059 was used. After the U87 MG cells
were cultured to ~80% confluency, they were pre-treated
with 20 µM ERK inhibitor PD98059 for 1 h followed by
the addition of 5 µM CPT for 24 h. Subsequently, cell
lysates underwent western blotting against cleaved PARP
to assess the effects of ERK activation on apoptosis. As
shown in Figure 6A and 6C, CPT-induced PARP cleavage
was significantly reduced after the cells were pre-treated
with PD98059. These results suggest that ERK activation
partially contributes to CPT-induced apoptosis (Figure 6B).

Figure 4: Niclosamide enhances p53 protein and cytochrome c expression but suppresses p21 expression. CPT strongly

promotes p53, p21, and cytochrome c expression. (A) U87 MG cells were treated with either 5 μM niclosamide (Nicl), 5 μM CPT, or a
combination of both for 24 hours. Thereafter, the cells were collected, and the cell lysate was prepared for Western blot analysis. The
proteins were resolved by SDS-PAGE and immunoblotted with specific antibodies against p21, p53, and cytochrome c. β-Actin was used
as the loading control. (B) p53 protein expression levels. (C) p21 protein expression levels. (D) Cytochrome c protein expression levels.
Data represent the mean ± S.E.M of three replicates. *p < 0.05; **p < 0.01; ***p < 0.001.
www.oncotarget.com
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CPT induces autophagy and suppresses
niclosamide-induced ER stress in U87 MG Cells

not stimulate ER stress and even suppress niclosamideinduced ER stress.

Autophagy serves an important role in cell
metabolism by degrading intracellular macromolecules
and damaged organelles to maintain cell homeostasis
[55]. Our previous study reported that niclosamide can
stimulate ER stress and autophagic apoptosis [19]. In the
present study, the potential effects of CPT on ER stress
and autophagy in U87 MG cells were next investigated.
ER stress was detected by measuring the expression of
CHOP, an ER stress marker. During autophagy induction,
LC3I is converted to LC3II, a marker widely used for
measuring autophagy. In the present study, autophagy
induction was confirmed by measuring LC3II expression.
U87 MG cells were first exposed to 5 µM niclosamide
and/or 5 µM CPT for 24 h. Thereafter, cell lysates were
collected for western blotting. Niclosamide was found to
upregulate the expression of CHOP and LC3II (Figure
7A), consistent with findings from our previous study
[19]. By contrast, CPT treatment was unable to affect
CHOP expression, whereas the increased levels of CHOP
expression triggered by niclosamide were significantly
reversed by CPT co-treatment (Figure 7B). Furthermore,
CPT was detected to modestly but significantly elevate
LC3II expression compared with that in the untreated
control group (Figure 7C). This suggests that CPT could

Differential effects of niclosamide and CPT on
the expression of cell cycle regulators
Cyclins D1 and D3 are important regulators of cell
cycle progression from G1 to S phases. Both regulators
serve as positive growth stimuli for cell cycle progression
and cell proliferation. Cyclin D1 and D3 have been
previously reported to be proto-oncogenes [56, 57]. In
our previous study, it was demonstrated that niclosamide
can inhibit cyclin D1 expression in U87 MG cells [19]. In
the present study, both cyclin D1 and cyclin D3 protein
expression were measured after the exposure of U87 MG
cells to 5 µM niclosamide and/or 5 µM CPT for 6–24 h.
As shown in Figure 8A, niclosamide potently suppressed
both cyclin D1 and cyclin D3 expession following 6 h of
treatment. However, unlike niclosamide, CPT only partially
inhibited cyclin D1 protein expression whilst significantly
enhancing cyclin D3 expression compared with those in
the control group (Figure 8A and 8B). Both cyclin D1
and D3 expression were reduced by combined treatment
compared with those in the control group. After exposing
the cells to niclosamide for 24 h, both cyclin D1 and D3
expression were abrogated, similar to the findings after 6 h
of treatment (Figure 8C). However, CPT treatment for 24

Figure 5: The effect of niclosamide and CPT on MAPK pathway. (A1) Niclosamide (Nicl) inhibits ERK phosphorylation,

whereas CPT induces abundant ERK phosphorylation. (A2) Densitometry analysis of p-ERK phosphorylation. (B1) Niclosamide slightly
upregulates JNK phosphorylation compared with control, whereas CPT dramatically increases JNK phosphorylation. The combined
treatment of the two synergistically upregulates JNK phosphorylation. (B2) Densitometric analysis of p-JNK. Total protein was isolated
from U87 MG cells treated with 5 μM niclosamide, 5 μM CPT, or their combination for 24 hours. Lysates were resolved by SDS-PAGE and
immunoblotted with antibodies, as indicated in the figures. *p < 0.05, **p < 0.01, and ***p < 0.001.
www.oncotarget.com
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h yielded cyclin D1 protein expression levels comparable
to those in the control group whilst enhancing cyclin D3
protein expression. In comparison to the 6 h combinatorial
treatment, cyclin D1 expression was almost completely
suppressed after 24 h of combined CPT and niclosamide
treatment (Figure 8A and 8C). Furthermore, cyclin
D3 expression was significantly reduced by combined
treatment, compared with that in the CPT treatment group
(Figure 8D). Taken together, these results suggest that
niclosamide had the capability to inhibit both cyclin D1
and D3 expression. By contrast, CPT temporarily inhibited
cyclin D1 expression but enhanced cyclin D3 expression.
Furthermore, combined treatment inhibited both cyclin D1
and D3 expression in U87 MG cells.

oncogenic signaling pathways in a synergistic manner.
This approach can also reduce drug resistance and drug
dosage in addition to lowering the overall cost. It was
previously demonstrated that niclosamide can serve as
a proteosome inhibitor to stimulate the accumulation
of ubiquitinated proteins, in turn inducing apoptosis,
ER stress and autophagy. Furthermore, niclosamide has
been shown to inhibit a multitude of survival signaling
pathways in human glioblastoma U87 MG cells [19].
Therefore, in the present study, these previous findings
were extended by investigating the combinatorial effects
of niclosamide and CPT treatment on U87 MG cells.
Previous studies have shown that niclosamide and CPT
are cytotoxic. Furthermore, they exhibit anticancer activity
by regulating a range of important cellular mechanisms in
various types of cancer cells. The aim of the present study
was to investigate the effects and underlying mechanism
of niclosamide and/or CPT on the glioblastoma cell line
U87 MG.
Our previous findings have shown that niclosamide
can induce cytotoxicity in U87 MG cells. In the present
study, the potential cytotoxic effects of niclosamide
combined with CPT in U87 MG cells was first evaluated.
Treatment with either niclosamide or CPT alone inhibited
cell viability in a dose-dependent manner (Figure 1),
whilst combined treatment of the two decreased cell

DISCUSSION
Glioblastomas belong to a family of malignancies in
the central nervous system with poor overall survival rates
and requires novel and effective therapeutic approaches
to tackle. One of the approaches to treat glioblastoma
is a combination therapy. Combination therapy refers
to a treatment strategy that combines ≥ two therapeutic
agents in a single regimen. This type of therapy has been
documented to increase efficacy compared with that
by monotherapeutic approaches by targeting multiple

Figure 6: The activation of ERK by CPT has no significant effect on cell apoptosis. U87 MG cells were pretreated with

20 µM ERK signaling pathway inhibitor PD98059 (PD) for 1 hour and followed by exposure of 5 µM CPT for 24 hours. The cells were
collected, and cell lysates were prepared for Western blot analysis. Antibodies used were indicated in Figure 8. (A) Western blot profile.
(B) Densitometric values for p-ERK. (C) Densitometric value for cleaved PARP. Data represent the mean ± S.E.M of three replicates. *p <
0.05; **p < 0.01; ***p < 0.001.
www.oncotarget.com
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viability further. In addition, as shown in Figure 2A,
distinct morphological changes were observed between
niclosamide- and CPT-treated U87 MG cells. After
treatment with niclosamide for 48 h, the majority of the
cells demonstrated a spherical shape, reduced cell volume
and cell density. CPT exposure induced senescencelike cell phenotypes, including flattened and enlarged
cell bodies in addition to intensive blebbing, which
were consistent with the findings of Morandi et al.
[58]. However, the apparent senescent cell morphology
disappeared after co-treatment with niclosamide. These
results suggest that the cell morphological changes
observed after combined treatment were likely to be
driven by different mechanisms downstream.
In our present study, CPT treatment, like
niclosamide, can lead to cell apoptosis in U87 MG
cells, which is also consistent with previous studies,
which revealed that CPT and its derivatives can induce
apoptosis in different cancer cell lines, including lung
cancer [31], human breast cancer MCF-7 [59] and
MDA-MB-231 [60] cells and human colon cancer
cells [38]. The combination of niclosamide and
CPT enhanced cytotoxicity in U87 MG cells further
and exhibited significant potentiating effects on the
induction of apoptosis, as evidenced by the observed
caspase-3 activation and PARP cleavage (Figure 3).
Since niclosamide has been previously identified to be

a promoter of protein ubiquitination and cell apoptosis
in U87 MG cells [19], the effects of CPT treatment
on niclosamide-induced protein ubiquitination were
next examined. Similar to the effects mediated by
niclosamide, administration of CPT also resulted in the
accumulation of ubiquitinated proteins. Although the
level of ubiquitinated proteins is significantly higher
compared with that in the control group, CPT-induced
ubiquitinated protein levels were substantially less
potent compared with those in niclosamide-induced cells
(Figure 3). The effect of CPT on the accumulation of
protein ubiquitination has not previously been reported in
U87 MG cells. The mechanism of CPT-induced protein
ubiquitination may be unique in human glioblastoma
cells. Studies have shown that protein ubiquitination
can serve a role in tumor cell proliferation, survival and
apoptosis [61]. In the present study, niclosamide- and
CPT-induced protein ubiquitination may be one of the
mechanisms for the induction of cytotoxicity in U87 MG
cells. However, the underlying mechanism of protein
ubiquitination following niclosamide and CPT treatment
in glioblastoma cells remain questions that require
further examination in future studies.
Apart from the ubiquitin-proteasome system,
other mechanisms can also be involved in regulating
cell apoptosis, such as the p53 pathway. Activated
p53 in turn triggers several responses, including cell

Figure 7: Niclosamide triggers ER stress, whereas CPT inhibits ER response in U-87 MG cells. Both niclosamide and

CPT induce the autophagic response in U-87 MG cells. (A) U87 MG cells were treated with 5 μM niclosamide (Nicl), 5 μM CPT, or their
combination for 24 hours, then collected for lysate preparation. Total cell lysates were resolved on SDS-PAGE and immunoblotted with
antibodies specific for CHOP and LC3. β-actin was used as the loading control. (B) Relative expression levels of CHOP. (C) Relative
expression of LC3II. Data represent the mean ± S.E.M of three replicates. ***p < 0.001.
www.oncotarget.com
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cycle arrest, senescence, differentiation and apoptosis
[62]. In the present study, p53 activation was measured
in niclosamide- and/or CPT-treated U87 MG cells.
Consistent with previous findings in different cell types
[38, 60, 63, 64], CPT strongly enhanced both p21 and p53
protein expression in the U87 MG cell line. By contrast,
niclosamide only modestly increased p53 expression
compared with that in CPT. In particular, niclosamide
treatment almost completely suppressed both basal p21
and CPT-induced p21 expression. This observation
suggests that niclosamide and CPT induce cell responses
through distinct mechanisms. It has been reported that p53
can enhance cell autophagy, induce cell senescence and
apoptosis [62, 65]. In terms of p21, downregulated p21
expression has been reported to induce autophagy whereas
sustained p21 activity is required for the induction of
senescence [24, 38]. Findings from the present study
regarding p53 and p21 suggest that niclosamide may
induce cell death by triggering cytotoxic autophagy
whilst CPT causes the development of cell senescence.
Furthermore, both niclosamide and CPT may ultimately
induce cell apoptosis through different mechanism.
Cytochrome c serves an important role in cell
death. A previous study found that teniposide and
various other chemotherapeutic agents can induce dosedependent increases in the expression of cytochrome c
upstream of cell death induction [66]. In the present study,
cytochrome c expression in U87 MG cells treated with
niclosamide and/or CPT was also measured by western

blotting 24 h after treatment. As shown in Figure 4,
niclosamide triggered a small increase in cytochrome c
expression, whereas CPT markedly increased cytochrome
c expression. In addition, combined treatment with both
drugs promoted cytochrome c expression further. The
increased level of cytochrome c expression is positively
associated with the levels of p53 protein expression in the
present study, suggesting that p53 is involved in mediating
U87 MG apoptosis. p53 and cytochrome c expression
are also found to be positively associated with caspase-3
activation and PARP cleavage. These findings suggested
that niclosamide and CPT can increase the expression of
p53 and cytochrome c, where high expression levels of
cytochrome c released into the cytoplasm in turn activate
the caspase-3/PARP cascade downstream. Therefore,
both niclosamide and CPT are likely to cause cell death
through the caspase-dependent mitochondrial pathway by
activating cytochrome c.
Accumulating evidence suggests that the p53 protein
can regulate MAPK signaling pathways in response to
cell stress. MAPK signaling pathways, including JNK,
p38 and ERK, regulate various cell responses, including
proliferation, migration, differentiation and apoptosis. In
the present study, significant increases in p53 expression
were observed in U87 MG cells treated with niclosamide
and/or CPT. Therefore, the effects of niclosamide and/
or CPT treatment on ERK and JNK phosphorylation/
activation were next evaluated. Consistent with findings
from a previous study, niclosamide downregulated

Figure 8: Niclosamide represses cyclin D1 expression, whereas CPT markedly enhances cyclin D3 expression. The cell
lysates were prepared from U87 MG cells treated with either 5 μM niclosamide (Nicl), 5 μM CPT, or their combination for 6 and 24 hours.
Samples were resolved by SDS-PAGE and immunoblotted with antibodies specific for cyclin D1 and cyclin D3. β-Actin was used as the
loading control. (A) Cell lysates from cells treated for 6 hours. (B) Statistical analysis of D1 and D3 expression of 6-hour treated cells. (C)
Cell lysates from cells treated for 24 hours. (D) Statistical analysis of cyclin D1 and D3 expression of 24-hour treated cells. Data represent
the mean ± S.E.M of three replicates. *p < 0.05; **p < 0.001; ***p < 0.001.
www.oncotarget.com
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ERK expression and activation (Figure 5A1 and 5A2).
Furthermore, it was found that niclosamide was able
to slightly enhance JNK phosphorylation (Figure 5B1
and 5B2). By contrast, CPT significantly increased
both ERK and JNK phosphorylation. This CPTinduced ERK activation can be suppressed by the ERK
inhibitor PD98059 (Figure 6). Although niclosamide
reduced the basal expression levels of ERK and ERK
phosphorylation, it could not influence CPT-induced ERK
phosphorylation in U87 MG cells following combined
CPT and niclosamide treatment. In addition, niclosamide
and CPT co-treatment significantly increased JNK
phosphorylation. It has been previously reported that
DNA damage induced by cisplatin can activate ERK1/2
and increase p53 protein expression [67], leading to p53mediated cellular responses [68]. After the U87 MG cells
were treated with CPT or both CPT and niclosamide,
it is possible that DNA damage was induced, which
activated the ERK signaling pathway to upregulate p53
expression and promote apoptosis. A previous study
demonstrated that under cellular stress, JNK-mediated
phosphorylation can stabilize and activate p53 to
promote programmed cell death [69, 70]. Results from
the present study are consistent with previous findings
reporting that niclosamide and CPT can upregulate JNK
phosphorylation, which is in turn positively associated
with the findings of increased p53 expression, cytochrome
c expression, caspase-3 activation and PARP cleavage in
the present study. These results suggest that in U87 MG
cells, CPT can induce apoptosis by activating the ERK
pathway, whereas both niclosamide and CPT can induce
apoptosis by upregulating JNK activation.
ER stress is another key regulator of apoptosis. A
number of anti-cancer therapies have been shown to be
associated with the induction of ER stress in tumor cells
[71]. Therapeutic induction of ER stress-induced apoptosis
has been shown to be beneﬁcial for killing cancer cells
[72]. Findings from the present study are consistent with
the hypothesis that niclosamide treatment triggered ER
stress, as evidenced by the elevated CHOP expression
observed. CHOP is an ER stress marker that is considered
to serve an important role in the induction of apoptosis
[73]. The present study suggests that niclosamide-induced
ER stress served a key role in inducing cytotoxicity and
cell death. However, CPT not only failed to induce ER
stress, but also reversed niclosamide-stimulated ER stress
(Figure 7). These results suggest that CPT induced U87
MG cytotoxicity through pathways other than ER stress.
ER stress has been reported to contribute to both
autophagy and apoptosis. Niclosamide was previously
observed to suppress p21 expression, which is known to
induce autophagy [24]. Therefore, the present study also
investigated the autophagic response after U87 MG cells
were treated with niclosamide and/or CPT. Consistent
with previous observations, expression of the autophagy
marker LC3II was markedly increased after the U87
www.oncotarget.com

MG cells were exposed to niclosamide. CPT treatment
also increased LC3II expression but this effect was not
as potent compared with niclosamide, suggesting that
CPT only serves a minor function on autophagy-induced
cytotoxicity. In addition, LC3II expression displayed
no clear difference between niclosamide and combined
treatment (Figure 7), indicating potent autophagy
activation in U87 MG cells treated with both drugs.
Since the level of LC3II expression in the combined
treatment associated positively with caspase-3 activation,
PARP cleavage and cytochrome c expression, autophagy
activation was likely to favor the induction of apoptosis
after the U87 MG cells were treated with both CPT and
niclosamide. Consistent with the results in U87 MG cells
in the present study, niclosamide was reported to stimulate
both apoptotic and autophagic cell death in HeLa cells
[74]. In addition, a number of studies have shown that
autophagy induced by anti-cancer drugs causes autophagic
cell death in glioma cells [75]. Qu et al. [76] also
reported that berberine-induced autophagy can reverse
temozolomide resistance in glioblastoma, suggesting
that autophagy upregulation can increase anticancer
drug sensitivity in previously drug-resistant cancer
cells. Therefore, autophagy stimulation may enhance the
efficacy of anticancer drug therapy. The present study
suggests that niclosamide can induce autophagy and
apoptosis through ER stress, which persisted after the
U87 MG cells were treated with both niclosamide and
CPT together.
D-type cyclins, which include Cyclins D1, D2
and D3, are regulators of cell cycle progression [77].
Their expression has been previously associated with
the prognosis in different types of cancers whilst also
being used for clinical diagnosis and treatment [78–81].
Several therapeutic agents have been shown to induce
cyclin D1 degradation in cancer cells. Therefore, the
present study investigated effects of niclosamide and
CPT on expression of D-type cyclins. Cyclin D1 and D3
were both found to be expressed in U87 MG cells, where
they were suppressed after treatment with niclosamide
for 6 and 24 h in U87 MG cells (Figure 8). This suggests
that niclosamide can either inhibit cyclin D1 and D3
expression or induced the degradation of both. Compared
with niclosamide, CPT only partially inhibited cyclin D1
expression 6 h after exposure, which returned to control
levels 24 h after exposure. In addition, cyclin D3 was
upregulated in response to CPT 6 h after treatment,
which remained high level even after 24 h. Since cyclin
D3 expression had no associations with cyclin D1, they
may function independently in U87 MG cells. Cyclin D1
has been recognized to be an important human protooncogene, such that cyclin D1 degradation is considered
to be a promising target for anticancer drugs [82]. By
contrast, cyclin D3 can function as a crucial regulator
of differentiation and proliferation in tumor cells [83].
It has been previously reported that cyclin D3 serves
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a pivotal role in the progression from G1 to S phase of
the cell cycle, which is implicated in tumor progression.
The present study revealed that niclosamide can
suppress both cyclin D1 and D3 expression, suggesting
that niclosamide could suppress cell proliferation
by destabilizing cyclin D1 and D3. As previously
documented by Shan et al. [84], ubiquitination of cyclin
D1 can induce proliferation suppression in cancer cells.
This may explain why increased ubiquitinated protein
levels were detected following niclosamide induction in
the present study.
A previous study has reported that the prognostic
role of cyclin D3 in neoplasms remains controversial
[85]. Activation of cyclin D3 can either promote cancer
cell survival or contribute to cancer cell death. It has been
reported that aberrant cyclin D3 expression was found
in various cancers, including leukemia, hepatocellular
carcinoma, gliomas, bladder carcinoma, prostate cancer,
osteosarcoma and breast cancer [85, 86]. This abnormal
cyclin D3 expression profile may reflect cell type-specific
differences under distinct experimental conditions. High
expression levels of cyclin D3 can sensitize cells to
apoptosis and stimulate the activation of caspase-2 by
direct interaction, where directed expression of cyclin D3
and caspase-2 in human cells potentiates apoptosis [87].
Olshavsky et al. [88] reported that cyclin D3 was able to
bind to and attenuate androgen receptor activity in prostate
cancer cells, where cyclin D3 overexpression inhibited cell
proliferation in androgen-dependent cells. In addition,
treatment with hydroxydibenzoylmethane, an apoptosis
inducer, stimulated cyclin D3 expression in human
colorectal carcinoma cells [89]. It was demonstrated for
the first time in the present study that cyclin D3 expression
was increased in response to CPT treatment in U87 MG
cells. At present, the role of this upregulation of cyclin
D3 expression by CPT remains uncertain. Since the
suppression of cyclin D3 expression enhanced cytotoxicity
in U87 MG cells, this may be due to an adaptive response
against CPT-indued apoptosis and senescence, which may
in turn be one of the mechanisms of chemoresistance
induction. Therefore, combination treatment with CPT
and niclosamide with cyclin D3 inhibition may serve as
a novel approach as a form of adjuvant therapy for GBM.
In conclusion, findings from the present study
suggested that niclosamide and CPT can exert cytotoxic
effects and prevent GBM progression through different
mechanisms. In addition, they appear to exhibit synergistic
anticancer effects in human glioblastoma U87 MG cells.
Niclosamide triggered cytotoxicity mainly through the
inhibition of pro-survival signaling pathways (PI3K/AKT,
Stat3 and Wnt/β-catenin) [19], induction of ER stress
and autophagy. By contrast, CPT induced cell apoptosis
and senescence mainly through the activation of proapoptotic cell signaling (MAPK/JNK), induction of p53
and cytochrome c expression. The combinatorial treatment
of niclosamide and CPT exerted significantly more potent
www.oncotarget.com

cytotoxic effects compared with treatment with either
agent alone in U87 MG cells. Findings from a previous
study [90] reported that niclosamide potentially serves a
neuroprotective function against proteasome inhibitioninduced apoptosis in human SH-SY5Y and rat PC12 neural
cells. This may confer another advantage for selecting
niclosamide as an anticancer agent for targeting glioblastoma
without damaging healthy neuronal cells. Therefore, the
combination of niclosamide and CPT or its derivatives may
be applied to overcome chemoresistance, minimize adverse
effects and treat glioblastoma in the future.

MATERIALS AND METHODS
Reagents
Niclosamide, CPT and PD 98059 were purchased
from Sigma-Aldrich; Merck KGaA. They were dissolved
in DMSO to 10 mM and stored at −20°C. MTT reagent
was purchased from R&D Systems, Inc. Super Signal
West Pico Plus chemiluminescence substrate was obtained
from Thermo Fisher Scientific, Inc.

Cell culture
The U87 MG cell line, which is a human glioblastoma
cell line with an unknown patient origin [91], was purchased
from the American Type Culture Collection (cat. no. ATCC
HTB-14). Cells were cultured at 5% CO2 at 37°C in DMEM
(Gibco; Thermo Fisher Scientific, Inc.) supplemented
with 10% FBS (Corning, Inc.), penicillin (100 U/ml) and
streptomycin (100 μg/ml). Cells were sub-cultured weekly
onto six-well or 100-mm tissue culture dishes and used for
subsequent experiments at 85–90% confluence.

Cell treatment and viability assays
U87 MG cells were first exposed to different
doses of niclosamide and CPT for 48 h. Cell viability
was then measured using the MTT assay, specifically
by colorimetry, according to manufacturer’s protocols.
Briefly, cells (8,000 cells in 200 μl DMEM per well)
were seeded into 96-well plates the day before the
experiment. Cells were then treated with 1, 1.25, 2.5,
5, 10 and 20 μM niclosamide or CPT for 48 h. At the
end of the treatment period, media were removed from
all wells, which was then followed by the addition of
100 μl DMEM containing 1 μl MTT reagent (1:100
dilution) into each well and incubation for 2 h at 37°C.
Thereafter, this media was removed and the cells were
lysed using 100 μl DMSO. Absorbance in each well was
then measured using a microplate reader at a wavelength
of 570 nm. In total, ≥ four replicates were performed for
each treatment. The concentrations for each drug were
then selected for combinatorial treatment in subsequent
experiments.
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Light microscopy

was considered to indicate a statistically significant
difference.

U87 MG cells were cultured either in the absence
of treatment (control cells) or in the presence of 5 µM
niclosamide and/or 5 µM CPT for 48 h in DMEM
supplemented with 10% FBS at 37°C. Morphological
changes of the cells were then observed and photographed
under an inverted phase-contrast light microscope.
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LV, and PC performed the experiments. XF analyzed
the data and performed the statistical analyses. BC and
XF drafted the manuscript, and all authors read and
commented on the manuscript. BC and XF confirm the
authenticity of all the raw data. All authors approved the
final manuscript.

Western blot analysis
Protein expression was measured using western
blot analysis. Protein homogenates were prepared
as follows: U87 MG cells were treated with 5 μM
niclosamide and/or 5 μM CPT for 6–24 h. Following
treatment, cells were lysed using ice-cold RIPA lysis
buffer (Santa Cruz Biotechnology, Inc.) containing
protease and phosphatase inhibitor cocktails (Santa
Cruz Biotechnology, Inc.). Clear lysates were obtained
by centrifugation at 4°C for 20 min at 40,000 g. Protein
concentrations were determined using the Pierce BCA
Protein Assay kit (Pierce; Thermo Fisher Scientific, Inc.)
according to the manufacturer’s protocol. Subsequently,
equal amounts of protein (20–30 μg) were separated
by 12% or 4–20% SDS-PAGE (Bio-Rad Laboratories,
Inc.), transferred onto nitrocellulose membranes and
blocked for 1 h at room temperature with TBS containing
0.1% Tween 20 (TBS-T; pH 7.4) and 5% (w/v) non-fat
dried milk or 5% BSA (Sigma-Aldrich; Merck KGaA).
The membranes were then incubated with specific
primary antibodies overnight at 4°C. Antibodies
against β-actin (SC-47778), ubiquitin (SC-8017), ERK
(SC-1647), cyclin D1 (SC-8396) and p53 (SC-126)
were purchased from Santa Cruz Biotechnology, Inc.,
whereas antibodies against cleaved-PARP (9542),
cleaved caspase-3 (9664), phosphorylated (p-)-ERK
(4370), p-JNK (9251), p21 (64016), CCAAT/enhancerbinding protein (CHOP, 2895), LC3 (2775), cyclin D3
(2936) and cytochrome c (4272) were obtained from Cell
Signaling Technology, Inc. After probing with primary
antibodies, the membranes were washed and incubated
for 1 h with corresponding HRP-conjugated secondary
antibodies (SC-2357 and SC-516102, Santa Cruz
Biotechnology, Inc.). The protein bands were detected
using a chemiluminescent (ECL) method (Super Signal
West Pico Plus chemiluminescence substrate) according
to the manufacturer’s protocol. Band intensities were
quantified using the ImageJ software (National Institutes
of Health, version: 2.0.0-rc-43/1.52n).
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